UPLC—MS/MS测定复方丹参方中丹参酮ⅡA、丹参酚酸B、人参皂苷Rg1及其在大鼠血浆和脑组织的药代动力学研究
2017-03-20张杰刘胜兰王慧阳国平李劲平刘世
张杰+刘胜兰+王慧+阳国平+李劲平+刘世坤+唐智+裴奇+黄攀豪



[摘要]建立大鼠血漿和脑组织中丹参酮Ⅱa(TSⅡa)、丹酚酸B(SAB)、人参皂苷Rg1(GRg1)的UPLC-MS/MS分析方法,并开展药物动力学研究。选用SD大鼠,单剂量灌胃(ig)复方丹参方,采集血液与脑组织样品,采用UPLC-MS/MS测定血浆和脑组织中TSⅡa、SAB和GRg1的浓度,以Phoenix WinNolin 6.1药动学程序软件对数据进行非房室模型拟合,采用统计矩法计算药动学参数。经方法学考证,3种成分的峰面积与其在血样及脑组织中的浓度线性关系良好(r>0.992 2);回收率为58.86%~112.1%,日内、日间RSD≤9.7%,准确度及稳定性均符合体内药物分析的要求。大鼠ig给复方丹参方后的血浆药动参数如下:丹参酮Ⅱatmax(1.58±0.081) h,Cmax(725.4±88.20) μg·L-1,AUC0-t(2 101.3±124.85) μg·h·L-1, MRT0-t(3.66±0.05) h;丹酚酸B tmax(1.29±0.21) h,Cmax(307.9±46.75) μg·L-1,AUC0-t(537.4±88.24) μg·h·L-1, MRTlast (2.08±0.11) h;人参皂苷Rg1tmax(1.42±0.20) h,Cmax(460.38±154.60) μg·L-1,AUC0-t(383.4±88.16) μg·h·L-1, MRTlast (1.87±0.046) h。脑组织药动参数如下:丹参酮ⅡA tmax(0.75±0.22) h,Cmax(1.41±0.420) ng·g-1,AUC0-t(4.34±2.48) ng·h·g-1, MRT0-t (4.00±1.90) h;丹酚酸B tmax(1.08±0.20) h,Cmax(21.09±4.850) ng·g-1,AUC0-t(14.83±3.160) ng·h·g-1, MRT0-t(0.99±0.08) h;人参皂苷Rg1tmax(0.50±0.16) h,Cmax(130.96±54.220) ng·g-1,AUC0-t(136.24±34.350) ng·h·g-1, MRT0-t(2.87±0.33) h。该研究所建立的UPLC-MS/MS方法可用于大鼠血浆及脑组织中丹参酮Ⅱa、丹酚酸B、人参皂苷Rg1中的药动学研究。
[关键词]UPLC-MS/MS; 丹参酮Ⅱa; 丹酚酸B; 人参皂苷Rg1; 药动学
[Abstract]A sensitive and specific ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) method was developed for analysis of tanshinone Ⅱa(TSⅡa), salvianolic acid B(SAB) and ginsenoside Rg1(GRg1) in rat plasma and brain tissues. Male healthy Sprague-Dawley(SD) rats were orally given single dose of Fufang Danshen preparation (TS Ⅱa 60 mg·kg-1, SAB 300 mg·kg-1, GRg1 150 mg·kg-1, borneol 300 mg·kg-1), and their blood samples and brain tissues were collected at different time points. The drug plasma and brain tissue concentrations of the three analytes were determined by UPLC-MS/MS method. Subsequently, the main pharmacokinetics parameters of plasma and brain tissues were calculated by using Phoenix WinNolin 6.1 software. The methodological test showed that all of analytes in both plasma and brain homogenate exhibited a good linearity within the concentration range(r>0.992 2). Their mean recoveries were between 58.86% and 112.1%. Intra-day and inter-day precisions of the investigated components exhibited RSD≤9.7%, and the accuracy(RE) ranged from -9.68% to 8.20% at all quality control levels. The results of accuracy and stability meet the requirements for biopharmaceutical analysis. For TSⅡa, the pharmacokinetics parameters tmax, Cmax, AUC0-t, MRTlast in the plasma were (1.58±0.081) h, (725.4±88.20) μg·L-1, (2 101.3±124.85) μg·h·L-1 and (3.66±0.05) h, respectively. For SAB, the pharmacokinetics parameters tmax, Cmax, AUC0-t, MRTlast in the plasma were (1.29±0.21) h, (307.9±46.75) μg·L-1, (537.4±88.24) μg·h·L-1 and (2.08±0.11) h, respectively. For GRg1, the pharmacokinetics parameters tmax, Cmax, AUC0-t, MRTlast in the plasma were (1.42±0.20) h, (460.38±154.60) μg·L-1, (383.4±88.16) μg·h·L-1 and (1.87±0.046) h, respectively. For TSⅡa, the pharmacokinetics parameters tmax, Cmax, AUC0-t, MRTlast in the brain tissue were (0.75±0.22) h, (1.41±0.42) ng·g-1, (4.34±2.48) ng·h·g-1 and (4.00±1.90) h, respectively. For SAB, the pharmacokinetics parameters tmax, Cmax, AUC0-t, MRTlast in the plasma were (1.08±0.20) h, (21.09±4.850) ng·g-1, (14.83±3.160) ng·h·g-1 and (0.99±0.08) h, respectively. For GRg1, the pharmacokinetics parameters tmax, Cmax, AUC0-t, MRTlast in the plasma were (0.50±0.16) h, (130.96±54.220) ng·g-1, (136.24±34.350) ng·h·g-1 and (2.87±0.33) h, respectively. The developed method was successfully applied in pharmacokinetic studies on content of TS Ⅱa, SAB and GRg1 in rat plasma and brain tissues.
[Key words]UPLC-MS/MS; tanshinone Ⅱa; salvianolic acid B; ginsenoside Rg1; pharmacokinetic
复方丹参方由丹参、三七和冰片3味中药组成,活血化瘀,理气止痛,被广泛用于冠心病、心复绞痛、脑缺血再灌注损伤、脑缺血、阿尔兹海默病等[1-3],疗效确切,《中国药典》1977年版至2015年版均有收载,且已列入国家基本药品目录。研究表明,丹参主要有效成分为丹参酮Ⅱa、隐丹参酮等脂溶性丹参酮类和丹参酚酸B、丹参素等水溶性丹参酚酸类,对心肌缺血、脑缺血以及脑缺血再灌注损伤具有明显的保护作用[4]。三七皂苷R1、人参皂苷Rg1和Rb1等三七皂苷类是三七的主要有效成分,具有改善微循环、抗血栓形成和扩张血管等作用[5]。冰片为佐使药,芳香走窜,“引药上行”。……p>
